Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observedSupports progression into Phase III development...
-
Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients No safety or tolerability concerns were observedSupports progression into Phase III development...
-
PRESS RELEASE Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate...
-
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public...
-
PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and...
-
PRESS RELEASE Memo Therapeutics increases Series C financing to CHF 45 million Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing...
-
PRESS RELEASE Memo Therapeutics increases Series C financing to CHF 45 million Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing...
-
PRESS RELEASE Memo Therapeutics AG Strengthens Management Team Appoints Kristie B. Clemmer as VP Clinical Operations and Dr. Maartje Verschuur as VP CMC and Supply Chain Management ...